Skip to main content
OpenTrials
Completed

NCT Number: NCT04643067

Phase 1b/2a Study to Evaluate Safety and Efficacy of KPG-818 in SLE

Study Title

A phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to assess the safety and tolerability, pharmacokinetics and preliminary efficacy of KPG-818 in patients with mild to moderate systemic lupus erythematosus

Completed

Looking for future studies?

Notify Me

Key information

Conditions

SLE; Drug drug-induced lupus

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Phase 1 / Phase 2

Primary location

Anniston Medical Clinic, Anniston, Alabama, United States

Loading trial locations.

About this study

This is a Phase 1b/2a multicenter study to evaluate the safety, PK, PD, and clinical efficacy of KPG-818 in patients with SLE. The trial will consist of 2 parts: Phase 1b, a multiple-ascending dose (MAD) study; and Phase 2a, a proof of concept (POC) study.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

are listed as follows:

  • Age≥18
  • BMI between 18-40kg/m²
  • Diagnosed with SLE according to the 2019 EULAR/ACR criteria for SLE
  • Meeting SLE activity requirements
  • Males and females childbearing potential must agree to use contraception methods
  • All patients must:
  • Understand that KPG-818 could have potential teratogenic risk.
  • Agree not to share KPG-818 with another person.
  • Be counseled about pregnancy precautions and risks of fetal exposure as described in the Pregnancy Prevention Plan.
  • Patients must agree not to donate blood (or any component of blood) from 3 months before Screening until 3 months after the last dose of KPG-818.
  • Patients must be willing to comply with precautions to reduce the risk of COVID-19 infection and to undergo COVID-19 PCR test.

Exclusion criteria

are listed as follows:

  • Use of any prohibited medications within the pre-specified time
  • Patients must meet exclusionary lab criteria
  • Active and/or unstable neuropsychiatric SLE
  • Active or history of severe systemic bacterial, viral, fungal, mycobacterial, or parasitic infections within 6 months prior to Screening
  • Current or recent sign or symptoms of infections, or severe viral infections
  • Conditions predisposes patient to infection
  • Active TB or positive QuantiFERON®-TB Gold test
  • Patients with malignancy and antiphospholipid syndrome history
  • Inflammatory joint or skin disease, mixed connective tissue disease, scleroderma, and/or overlap syndromes, or acute or chronic disease
  • Concomitant condition that required systemic corticosteroid use within 1 year before Screening
  • Alcohol or drug abuse history
  • Positive urine drug test at screening
  • History or planned major surgery
  • Pregnant or breastfeeding female
  • Signs or symptoms of COVID-19 infection
  • Known allergic reaction to any of the ingredients for study drug or placebo

Treatment and study plan

KPG-818 low dose

Drug

The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.

KPG-818 mid dose

Drug

The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.

KPG-818 high dose

Drug

The dose levels may be modified according to the results from phase 1b of the study. Dose adjustment is allowed during the study.

Placebo

Drug

This is the comparative arm.

Primary outcomes

  1. Safety assessment by the occurrence of adverse events (AEs)

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    To calculate the occurrence rate of adverse events (AEs)

  2. Safety assessment by the changes from baseline in laboratory parameters

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    To calculate the occurrence rate of out of normal ranges of laboratory parameter changes from baseline.

  3. Safety assessment by out of normal range of vital signs

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    To calculate the occurrence rate of out of normal range of vital signs from baseline.

  4. Safety assessment by out of normal range of ECG results

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    To calculate the occurrence rate of out of normal range of ECG results.

  5. PK profile of time to peak (Tmax) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured on Day 1 after dose administration and after the plasma concentration reaches a steady state.

  6. PK profile of peak plasma concentration (Cmax) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured on Day 1 after dose administration.

  7. PK profile of elimination half-life (t1/2) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured on Day 1 after dose administration and after the plasma concentration reaches a steady state.

  8. PK profile of the area under the concentration-time curve (AUC0-24h) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured on Day 1 after dose administration.

  9. PK profile of the mean retention time (MRT) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured after the plasma concentration reaches a steady state.

  10. PK profile of trough concentrations at steady state (Css_min) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured after the plasma concentration reaches a steady state.

  11. PK profile of peak concentrations at steady state (Css_max) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured after the plasma concentration reaches a steady state.

  12. PK profile of the area under the concentration-time curve at steady state (AUCτ, AUC0-∞) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured after the plasma concentration reaches a steady state.

  13. PK profile of the clearance (CL/F) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured after the plasma concentration reaches a steady state.

  14. PK profile of the apparent volume of distribution ((Vz/F) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured after the plasma concentration reaches a steady state.

  15. PK profile of the cumulative coefficient (R) for KPG-818 and KPG-818H (if applicable).

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    This will be measured after the plasma concentration reaches a steady state.

  16. Assess the proportion of patients with improvement of clinical scores of SELENA-SLEDAI (safety of estrogens in lupus national assessment-systemic lupus erythematosus disease activity index) improvement ≥ 4 points from baseline at Week 12.

    Time frame: 16 weeks for phase IIa

    To calculate the proportion of patients with SELENA-SLEDAI (safety of estrogens in lupus national assessment-systemic lupus erythematosus disease activity index) improvement ≥ 4 points from baseline at Week 12. Note: the SELENA-SLEDAI scale ranges from 0~105, with 105 as the highest disease activity.

Secondary outcomes

  1. Mean change from baseline in PGA (Physician Global Assessment) score at Week 12.

    Time frame: 16 weeks for phase IIa

    Mean change from baseline in PGA (Physician Global Assessment) score at Week 12. Note: the PGA is a visual scale for the physician to mark, from 0mm to 100mm, with 0mm being no disease activity and 100mm being the extreme disease activity.

  2. The proportion of patients with a ≥ 50% reduction from baseline in CLASI (Cutaneous Lupus erythematosus disease Area and Severity Index) activity score at Week 12, in patients with baseline CLASI activity score ≥ 10.

    Time frame: 16 weeks for phase IIa

    The proportion of patients with a ≥ 50% reduction from baseline in CLASI (Cutaneous Lupus erythematosus disease Area and Severity Index) activity score at Week 12, in patients with baseline CLASI activity score ≥ 10. Note: the total CLASI score ranges from 0 to 114, with 0 being the least disease activity and 114 being the most.

  3. Number of patients with adverse event at Week 12

    Time frame: 12 weeks for phase IIa

    Number of patients with adverse event at Week 12

  4. Number of patients with adverse event at Week 16.

    Time frame: 16 weeks for phase IIa

    Number of patients with adverse event at Week 16.

  5. The PK endpoint of the measurement of area under the curve (AUC) at Week 12 (AUC0-last) for assessment of KPG-818 and KPG-818H (if applicable).

    Time frame: 12 weeks for phase IIa

    The PK endpoint of the measurement of area under the curve (AUC) at Week 12 (AUC0-last) for assessment of KPG-818 and KPG-818H (if applicable).

  6. The PK endpoint of the maximum observed concentration (Cmax) at Week 12 for assessment of KPG-818 and KPG-818H (if applicable)

    Time frame: 12 weeks for phase IIa

    The PK endpoint of the maximum observed concentration (Cmax) at Week 12 for assessment of KPG-818 and KPG-818H (if applicable)

  7. The PK endpoint of time to Cmax (tmax) at Week 12 for assessment of KPG-818 and KPG-818H (if applicable)

    Time frame: 12 weeks for phase IIa

    The PK endpoint of time to Cmax (tmax) at Week 12 for assessment of KPG-818 and KPG-818H (if applicable).

  8. The PK endpoint of Ctrough throughout the dosing period for assessment of KPG-818 and KPG-818H (if applicable)

    Time frame: 12 weeks for phase IIa

    The PK endpoint of Ctrough throughout the dosing period for assessment of KPG-818 and KPG-818H (if applicable)

  9. The PK endpoint of serum concentrations by scheduled timepoints for assessment of KPG-818 and KPG-818H (if applicable)

    Time frame: 12 weeks for phase IIa

    The PK endpoint of serum concentrations by scheduled timepoints for assessment of KPG-818 and KPG-818H (if applicable)

Other outcomes

  1. Explore the mean change from baseline in potential biomarker, i.e. Aiolos, of KPG-818 in PBMCs and CD19+ B Cells at Week 2.

    Time frame: 2 weeks for phase Ib

    Explore the mean change from baseline in potential biomarker of Aiolos of KPG-818 in PBMCs and CD19+ B Cells at Week 2.

  2. Explore the mean change from baseline in potential biomarker, i.e. Ikaros, of KPG-818 in PBMCs and CD19+ B Cells at Week 2.

    Time frame: 2 weeks for phase Ib

    Explore the mean change from baseline in potential biomarker, i.e. Ikaros, of KPG-818 in PBMCs and CD19+ B Cells at Week 2.

  3. Explore the mean change from baseline in potential biomarker, i.e. CRBN proteins, of KPG-818 in PBMCs and CD19+ B Cells at Week 2.

    Time frame: 2 weeks for phase Ib

    Explore the mean change from baseline in potential biomarker, i.e. CRBN proteins, of KPG-818 in PBMCs and CD19+ B Cells at Week 2.

  4. Mean change from baseline in potential biomarker, i.e. CRBN proteins, of KPG-818 in PBMCs and CD19+ B cells at week 12

    Time frame: 12 weeks for phase IIa

    Mean change from baseline in potential biomarker, i.e. CRBN proteins, of KPG-818 in PBMCs and CD19+ B cells at week 12

  5. Mean change from baseline in potential biomarker, i.e. Aiolos, of KPG-818 in PBMCs and CD19+ B cells at week 12

    Time frame: 12 weeks for phase IIa

    Mean change from baseline in potential biomarker, i.e. Aiolos, of KPG-818 in PBMCs and CD19+ B cells at week 12

  6. Mean change from baseline in potential biomarker, i.e. Ikaros, of KPG-818 in PBMCs and CD19+ B cells at week 12

    Time frame: 12 weeks for phase IIa

    Mean change from baseline in potential biomarker, i.e. Ikaros, of KPG-818 in PBMCs and CD19+ B cells at week 12

  7. Mean change from baseline in absolute counts of CD 19+ B cell and CD3+ T cell at week 12

    Time frame: 12 weeks for phase IIa

    Mean change from baseline in absolute counts of CD 19+ B cell and CD3+ T cell at week 12

  8. Mean change from baseline in IgA, IgG and IgM in serum at week 12

    Time frame: 12 weeks for phase IIa

    Mean change from baseline in IgA, IgG and IgM in serum at week 12

  9. Dose regimens for a Phase 2b/phase 3 study

    Time frame: 4 weeks for phase Ib and 16 weeks for phase IIa

    Dose regimens for a Phase 2b/phase 3 study

Sponsors and collaborators

Lead sponsor

Kangpu Biopharmaceuticals, Ltd.

Industry

Registry information

Official study title

A Phase 1b/2a Multicenter Study to Assess the Safety and Tolerability, Pharmacokinetics, and Preliminary Efficacy of KPG-818 in Patients With Systemic Lupus Erythematosus

Acronym: Lupus

Important dates

Study start
2021
Primary completion
2023
Study completion
2023
First posted
Nov 24, 2020
Registry last updated
May 23, 2024

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.